Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | OSBP | P22059 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 5/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775713 | 0.86 | POLA1 (0.48) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL17779818 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL22292582 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL22644915 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL16306911 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL24081051 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL22292578 | 0.84 | POLA1 (0.69) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL24503452 | 0.80 | POLA1 (0.51) | POLA1NPC1L1CYP46A1GBA1UGCG | |
| SCHEMBL13391627 | 0.77 | POLA1 (0.53) | POLA1NPC1L1CYP46A1USP2LMNA | |
| SCHEMBL14641136 | 0.77 | POLA1 (0.53) | POLA1NPC1L1CYP46A1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | Akamara Therapeutics, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190002489-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | AKAMARA THERAPEUTICS INC (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885NPC1L1 160/4885CYP46A1 1184/4885 |
| US-20190002489-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885NPC1L1 160/4885CYP46A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.